Adrenal myelolipoma: Difference between revisions
No edit summary |
m (Robot: Changing Category:DiseaseState to Category:Disease) |
||
Line 29: | Line 29: | ||
{{SIB}} | {{SIB}} | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Disease]] |
Revision as of 16:54, 12 December 2011
Adrenal myelolipoma |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Adrenal myelolipoma is a rare benign neoplasm. It is made up of mature adipose tissue and a variable amount of hematopoietic elements. Most lesions are small and asymptomatic. They are usually discovered incidentally at autopsy or on imaging studies performed for other reasons. Most tumors are unilateral but show no predilection to one particular side. Tumor size varies from several millimeters to more than 30 cm.
Epidemiology and Demographics
The incidence varies from 0.08-0.4% at autopsy.
Pathophysiology & Etiology
A myelolipoma may represent a site of extramedullary hematopoiesis. The most widely accepted theory is the existence of metaplasia of the reticuloendothelial cells of blood capillaries in the adrenal gland in response to stimuli such as necrosis, infection, or stress.